Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

RIGL 10.31.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-07
Name of Upcoming Event:Rigel Pharmaceuticals, Inc. Conference Call and Webcast
Full Press ReleaseSEC FilingsOur RIGL Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease
  • 01.13.2025 - Rigel Provides Business Update and 2025 Outlook
  • 01.09.2025 - Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Download as PDFOctober 31, 2024 8:05am EDT

SOUTH SAN FRANCISCO, Calif.,Oct. 31, 2024/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website atwww.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About RigelRigelPharmaceuticals, Inc. (Nasdaq:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996,Rigelis based in South San Francisco, California. For more information onRigel, the Company's marketed products and pipeline of potential products, visitwww.rigel.com.

Contact for Investors & Media:Investors:RigelPharmaceuticals, Inc.650.624.1232ir@rigel.com

Media:David RosenArgot PartnersPhone: 646.461.6387Email:david.rosen@argotpartners.com

Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2024-financial-results-and-business-update-302292332.html

SOURCE Rigel Pharmaceuticals, Inc.

Released October 31, 2024

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com